Archives: Products

Development of a biodegradable implant for the delivery of GLP-1 agonists, indicated for the treatment of metabolic syndrome. For the active ingredient, promising results from feasibility and human pharmacokinetic studies are available.

Not disclosed

Goserelin ready-to-use applicator in approval process for Latin America

mRNA eluting biodegradable implant as a next-generation gene therapy pathway. Prototyping and plausibility studies concluded.

Development of a biodegradable implant for the delivery of GLP-1 agonists, indicated for the treatment of metabolic syndrome. The feasibility study is expected shortly.